SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2012 / Cilt: 21 - Sayı: 1

Is sirolimus-tacrolimus combination superior to sirolimus-cyclosporine combination in patients with renal transplantation during early post-transplantation stage?

Böbrek nakli hastalarında nakil sonrası erken dönemde sirolimus-tacrolimus kombinasyonu sirolimus-siklosporin kombinasyonundan üstünmüdür?

Vural Taner YILMAZ
Gültekin SÜLEYMANLAR
Fevzi ERSOY
Alihan GÜRKAN
Ayhan DİNÇKAN
Hüseyin KOÇAK
Pages
45–52
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The frequency rate of glomerular filtration rates, proteinuria, serum hemoglobine, albumine and cholesterol levels, post-transplant diabetes mellitus was found to be similar.CONCLUSION: Concomitant use of sirolimus and tacrolimus during the early post-transplant stage showed similar efficiency and safety in short- and long-term compared to combination with cyclosporine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Our aim is to compare efficiency and safety of SRL+Tacrolimus (TAC) combination with that of Sirolimus (SRL) + Cyclosporin (CSA) combination during the early post-transplantation stage (first 3 months).MATERIAL and METHODS: Between 2005 and 2009, 156 patients (F/M: 49/107) who underwent a renal transplantation from a living donor and who were given sirolimus-based immunosuppressive therapy were enrolled in our study.
📊
Key Findings & Data:The patients were examined in two groups: Group 1: TAC+SRL: 57(36,5%), Group 2: CSA+SRL: 99(63,5%).
💡
Conclusion & Impact:The frequency rate of glomerular filtration rates, proteinuria, serum hemoglobine, albumine and cholesterol levels, post-transplant diabetes mellitus was found to be similar.CONCLUSION: Concomitant use of sirolimus and tacrolimus during the early post-transplant stage showed similar efficiency and safety in short- and long-term compared to combination with cyclosporine.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Our aim is to compare efficiency and safety of SRL+Tacrolimus (TAC) combination with that of Sirolimus (SRL) + Cyclosporin (CSA) combination during the early post-transplantation stage (first 3 months).MATERIAL and METHODS: Between 2005 and 2009, 156 patients (F/M: 49/107) who underwent a renal transplantation from a living donor and who were given sirolimus-based immunosuppressive therapy were enrolled in our study. The patients were examined in two groups: Group 1: TAC+SRL: 57(36,5%), Group 2: CSA+SRL: 99(63,5%). After Month 3, the therapy was continued with SRL+Mycophenolic acid+Prednisolone. Analyses were performed using the 3 year data of the patients.RESULTS: Demographic data of the groups were similar. The incidences of acute rejection (respectively, 15,8%- 21,2% in group 1 and 2; p:0,480), patient survival (100%-98%; p:0,280), graft survival (98,2%- 98%; p:0,698) were not found significantly different. The frequency rate of glomerular filtration rates, proteinuria, serum hemoglobine, albumine and cholesterol levels, post-transplant diabetes mellitus was found to be similar.CONCLUSION: Concomitant use of sirolimus and tacrolimus during the early post-transplant stage showed similar efficiency and safety in short- and long-term compared to combination with cyclosporine.

Özet

AMAÇ: Çalışmamızda böbrek nakli hastalarında erken nakil sonrası dönemde (ilk 3 ay) Sirolimus (SRL)+ Siklosporin (CSA) kombinasyonuna karşın SRL+ Tacrolimus (TAC) kombinasyonunun etkinlik ve güvenilirliğinin karşılaştırılması amaçlanmıştır.GEREÇ ve YÖNTEMLER: Çalışmamıza 2005-2009 yılları arasında merkezimizde canlıdan böbrek nakli yapılmış ve sirolimus bazlı bağışıklık baskılayıcı tedavi kullanan 156 hasta (F/M: 49/107) alındı. Hastalar iki grupta incelendi: Grup 1: TAC+SRL: 57 (%36,5), Grup 2: CSA+SRL: 99 (%63,5). İmmunosupresif tedavi protokolü olarak; ilk 5 gün kalsinörin inhibitörleri(KNI)+ Mikofenolik asid (MFA)+ Prednisolone kullanıldı. 6. günde MFA kesilirken SRL başlandı. KNI'leri 2.aydan sonra doz azaltılarak 3.ayda kesildi. 80.günde MFA %25 doz indirimi ile yeniden tedaviye eklendi. 3.aydan sonra tedaviye SRL+ MFA+ Prednisolone olarak devam edildi. Hastaların 3 yıllık verileri ile analizler yapıldı.BULGULAR: Grupların demografik özellikleri benzerdi. Akut rejeksiyon sıklığı (grup 1-2 sırayla %15,8- %21,2; p:0,480), hasta sağkalımı (%100-%98; p:0,280), greft sağkalımı (%98,2-98%; p:0,698), gecikmiş greft işlevi (%14-%20,2; p:0,334), yeni başlangıçlı nakil sonrası diyabetes mellitus (NSDM) (%14-%8,1; p:0,238) sıklıkları arasında anlamlı farklılık yoktu. Glomerüler filtrasyon hızları (GFH), kreatinin, proteinüri, hemoglobin, albümin, LDL kolesterol, trigliserid ve toplam kolesterol düzeyleri benzer bulundu.SONUÇ: Çalışmamızda sirolimus ile tacrolimusun erken nakil sonrası dönemde birlikte kullanımı kısa ve uzun vadede siklosporin ile kombinasyona göre etkinlik ve güvenilirlik açısından benzer bulunmuştur.

🔖

Cite This Article

YILMAZ, V. T., SÜLEYMANLAR, G., ERSOY, F., GÜRKAN, A., DİNÇKAN, A., KOÇAK, H. (2022). Is sirolimus-tacrolimus combination superior to sirolimus-cyclosporine combination in patients with renal transplantation during early post-transplantation stage?. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 21 - Sayı: 1, 45–52. https://ajindex.com/articles/636380

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP
  2. Sirolimus Renal Function Study Group: Improved renal function in sirolimus- treated renal transplant patients after early cyclosporine elimination. Transplantation 2002
  3. 74 (11): 1560-1567 2. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT
  4. Rapamune Maintenance Regimen Study Group: Long- term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003
  5. 76 (2): 364-370 3. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF
  6. ELITE-Symphony Study: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007
  7. 357 (25): 2562-2575 4. American Diabetes Association: Report of the Expert Committeeon the diagnosis and classification of the diabetes mellitus. Diabetes Care 2003
  8. 20 5. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg- Alberts R, Li H, Scarola J, Neylan JF
  9. Sirolimus CONVERT Trial Study Group: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009
  10. 87 (2): 233-242 6. Flechner SM, Kobashigawa J, Klintmalm G: Calcineurin inhibitor- sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008
  11. 22 (1): 1-15 7. Egbuna OI, Davis RB, Chudinski R, Pavlakis M, Rogers C, Molakatalla P, Johnson SR, Karp S, Monaco AP, Tang H, Hanto DW, Mandelbrot DA: Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Transplantation 2009
  12. 88 (5): 684-692 8. Chhabra D, Grafals M, Cabral B, Leventhal J, Parker M, Gallon L: Late conversion of tacrolimus to sirolimus in a prednisone- free immunosuppression regimen in renal transplant patients. Clin Transplant 2010
  13. 24 (2): 199-206 9. Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A: Conversion From Calcineurin Inhibitors to Sirolimus in Kidney Transplant Recipients: A Retrospective Cohort Study. Transplant Proc2009
  14. 3310 10. Mulay AV, Hussa